CYP2D6与他莫昔芬疗效相关性的研究进展  

Advances in correlation between CYP2D6 and tamoxifen therapy

作　　者：雷蕾[1] 王晓稼[1] 

机构地区：[1]浙江中医药大学附属肿瘤医院肿瘤内科,杭州310022

出　　处：《癌症进展》2009年第1期62-65,55,共5页Oncology Progress

基　　金：中国女性乳腺癌CYP2D6基因多态性与三苯氧胺代谢及疗效相关性研究(2008B020)

摘　　要：CYP2D6是一种重要的P450系氧化代谢酶,是他莫昔芬在体内代谢成更强抗雌激素作用代谢产物endoxifen的重要代谢酶,因此,强代谢乳腺癌患者服用他莫昔芬后引起明显的潮热症状,而潮热症状的发生与他莫昔芬疗效正相关。除了CYP2D6基因多态性可能影响他莫昔芬体内的代谢外,帕罗西汀(paroxetine)可竞争性抑制CYP2D6对他莫昔芬的代谢,使乳腺癌患者对他莫昔芬疗效明显降低。CYP2D6 is an important P450 cytochrome oxidases. It is the key enzyme in the transformation of tamoxifen to endoxifen, which has stronger anti-estrogen effect. Therefore, extensive metabolizers tend to have obvious hot flashes after tamoxifen treatment, which is positively correlated with the outcome of tamoxifen. CYP2D6＇s polymorphyism may influence the endo-metabolism of tamoxifen, and paroxetine may remarkably decrease the efficacy of tamoxifen by competitively inhibiting CYP2D6.

关 键 词：CYP2D6 基因多态性 他莫昔芬 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]